Hims & Hers Health (HIMS) is quickly becoming one of the most compelling stories in the market as an emerging powerhouse in the direct-to-consumer healthcare space. The stock has posted outsized gains ...

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 4.1% in the morning session after the company announced ...

From a receding hairline to thinning crown and balding, hair loss can be a difficult personal experience for many men as they ...

Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a ...

Bank of America names its highest-conviction stock ideas for Q3 2025—8 Buys and 2 Underperforms. Boeing, Cisco, and Datadog ...

HAVERI: The Haveri Institute of Medical Sciences (HIMS) is experiencing a critical shortage of cadavers for anatomy ...

Hims & Hers announced plans to expand its weight loss program to Canada in 2026 in connection with the availability of generic semaglutide anywhere in the world.

Seeking Alpha's daily roundup of remarks and statements that could impact markets, sectors or individual stocks. Read more ...

The move follows a dramatic breakup in June between Hims & Hers and Danish drug maker Novo Nordisk, which makes the brand name weight loss drug Wegovy. Novo Nordisk accused the Hims & Hers of ...

Shkreli's Turing Pharmaceuticals raised the price of an anti-parasitic drug from $13.50 to over $750 overnight, sparking ...

Analysts said the deal with Novo was likely giving Hims “‘credibility’ or increased consumer traffic,” adding that the ...

The medication finasteride has become popular among young men. But for those struggling to conceive, it could be the reason.